Precursor Condition
High Grade Intraepithelial Neoplasia
CI-CAN-00000992Explore in graph →
Precursor22 active trials
- NCIt
- C7348
Loading cancer entity…
Loading cancer entity…
Precursor Condition
CI-CAN-00000992Explore in graph →
Clinical trials
102 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05334004 | Lopinavir/Ritonavir in PLWH With High-Grade AIN | recruiting | Phase 1 | 21 | University of Wisconsin, MadisonOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT05717621 | Clinical Trial With Local Decitabine Treatment of HPV-Induced VIN Grade 2/3 (DelVIN)(DelVIN) | completed | Phase 1 | 29 | ViMREX GmbHINDUSTRY | 1 | Feb 11, 2025 | clinicaltrials |
| NCT05362955 |
| 5-fluorouracil Following Cervical Intraepithelial Neoplasia Treatment Among HIV-positive Women in East Africa |
| completed |
| Phase 1 |
| 12 |
| UNC Lineberger Comprehensive Cancer CenterOTHER |
| 1 |
| Aug 23, 2024 |
| clinicaltrials |
| NCT06273553 | A Study in Subjects With Human Papillomavirus 16 or 18 Associated Cervical Intraepithelial Neoplasia Grade 2 or 3 | not yet recruiting | Phase 1 / Phase 2 | 39 | RinuaGene Biotechnology Co., Ltd.INDUSTRY | 0 | Feb 22, 2024 | clinicaltrials |
| NCT02529930 | An Exploratory Safety and Immunogenicity Study of HPV16+ Immunotherapy VB10.16 in Women With HSIL; CIN 2/3) | completed | Phase 1 / Phase 2 | 34 | Nykode Therapeutics ASAINDUSTRY | 1 | Jul 13, 2022 | clinicaltrials |
| NCT02354534 | Intravaginal Artesunate for the Treatment of HPV+ High Grade Cervical Intraepithelial Neoplasia (CIN2/3) | completed | Phase 1 | 30 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT03697226 | Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection. | completed | Phase 1 | 8 | Antiva BiosciencesINDUSTRY | 1 | Jan 13, 2021 | clinicaltrials |
| NCT03676101 | Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females | completed | Phase 1 | 90 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT03677960 | Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection | terminated | Phase 1 | 6 | Antiva BiosciencesINDUSTRY | 2 | Jul 24, 2019 | clinicaltrials |
| NCT03239223 | Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection | completed | Phase 1 | 16 | Antiva BiosciencesINDUSTRY | 2 | Jul 10, 2019 | clinicaltrials |
| NCT03202992 | Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection | completed | Phase 1 | 57 | Antiva BiosciencesINDUSTRY | 2 | Feb 7, 2019 | clinicaltrials |
| NCT03141463 | Vvax001 Cancer Vaccine in (Pre) Malignant Cervical Lesions | completed | Phase 1 | 12 | University Medical Center GroningenOTHER | 1 | May 3, 2018 | clinicaltrials |
Data updated 22 days agoSource updated May 15, 2026source: clinicaltrials